Análise dos efeitos antidepressivos de novos compostos

Abstract

Depression, as well as other neuropsychiatric disorders, has been among the main health problems in the world's population. This process is complex and formed by its biological, social, psychic, and spiritual status, and is embedded in an unpredictable reality that carries several risk factors, from social acceptance to pandemic diseases. The treatments for depression are drug therapy and psychotherapy, however, there is low acceptance to the treatment, which have slow clinical effects and side effects. That said, this paper aims to clarify about the drugs ketamine, dronabinol and buprenorphine, evaluating if those have antidepressant effects, its cooperative mechanisms and side effects from the treatment. It is an qualitative study of systematic bibliographical review, consequently, it was done an extensive literature analysis, coordinately, thorough way, and to this end, articles published between 2010 and 2022 were reviewed, researched in the following scientific databases: Pubmed, Biblioteca Virtual em Saúde (BVS), Google Acadêmico, all in Portuguese, English, and Spanish, as well as the inclusion of dissertations, theses, and books in the psychiatry and pharmacology areas. The results showed that both ketamine, in its (R)-ketamine isomer, buprenorphine and creatine have antidepressant effects, on the other hand, dronabinol still has a controversial action. Therefore, it is concluded that comparative studies that show an advantage in efficacy and safety or cost-effectiveness about the drugs aforementioned should be incentivized, so that some of these stop being off label and become inserted into the therapeutic scheme of depression.